Novel possible pharmaceutical research tools: Stem cells, gene delivery and their combination

Current Pharmaceutical Design

Volumn 19, Issue 1, 2013, Pages 133-141

  Varga, Gábor ^a   Bori, Erzsébet ^a   Kálló, Karola ^a   Nagy, Krisztina ^a   Tarján, Ildikó ^a   Rácz, Gábor Z ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Adult stem cell; Delivery; Dental pulp; Embryonic; Epithelial function; Gene therapy; Human; Induced pluripotent; Mesenchymal; Neuronal differentiation; Regeneration; Salivary glands; Stem cell; Tissue damage

Indexed keywords

ADULT STEM CELL; CELL CULTURE; CELL DIFFERENTIATION; EMBRYONIC STEM CELL; FETAL STEM CELL; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PLURIPOTENT STEM CELL; POSTNATAL STEM CELL; PRIORITY JOURNAL; REVIEW; SALIVARY GLAND; STEM CELL; STEM CELL CULTURE; STEM CELL RESEARCH; TISSUE REGENERATION; TOOTH PULP;

EID: 84873969505     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811306010133     Document Type: Review

References (115)

1. Goodell MA. Multipotential stem cells and 'side population' cells. Cytotherapy 2002; 4: 507-8.
2. Javazon EH, Beggs KJ and Flake AW. Mesenchymal stem cells: paradoxes of passaging. ExpHematol 2004; 32: 414-25.
3. Kuehnle I and Goodell MA. The therapeutic potential of stem cells from adults. BMJ 2002; 325: 372-6.
4. Le Blanc K and Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005; 7: 36-45.
5. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99: 2344-9.
6. Aboody K, Capela A, Niazi N, Stern JH and Temple S. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a Rosetta Stone. Neuron 2011; 70: 597-613.
7. Blum B and Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008; 100: 133-58.
8. Grinnemo KH, Kumagai-Braesch M, Mansson-Broberg A, et al. Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod Biomed Online 2006; 13: 712-24.
9. Grinnemo KH, Sylven C, Hovatta O, Dellgren G and Corbascio M. Immunogenicity of human embryonic stem cells. Cell Tissue Res 2008; 331: 67-78.
10. Blum B, Bar-Nur O, Golan-Lev T and Benvenisty N. The antiapoptotic gene survivin contributes to teratoma formation by human embryonic stem cells. Nat Biotechnol 2009; 27: 281-7.
11. Takahashi K and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76.
12. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451: 141-6.
13. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
14. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118: 3132-42.
15. Modlich U and Baum C. Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest 2009; 119: 755-8.
16. Okita K, Nakagawa M, Hyenjong H, Ichisaka T and Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-53.
17. Stadtfeld M, Nagaya M, Utikal J, Weir G and Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322: 945-9.
18. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797-801.
19. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-6.
20. Vierbuchen T, Ostermeier A, Pang ZP, et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-41.
21. Nagy A and Nagy K. The mysteries of induced pluripotency: where will they lead? Nat Methods 2010; 7: 22-4.
22. Glowacki J and Mizuno S. Collagen scaffolds for tissue engineering. Biopolymers 2008; 89: 338-44.
23. Bianco P, Riminucci M, Gronthos S and Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. Stem Cells 2001; 19: 180-92.
24. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-4.
25. Hipp J and Atala A. Sources of stem cells for regenerative medicine. Stem Cell Rev 2008; 4: 3-11.
26. Vemuri MC, Chase LG and Rao MS. Mesenchymal stem cell assays and applications. Methods Mol Biol 2011; 698: 3-8.
27. Gronthos S, Mankani M, Brahim J, Robey PG and Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000; 97: 13625-30.
28. Kadar K, Kiraly M, Porcsalmy B, et al. Differentiation potential of stem cells from human dental origin-promise for tissue engineering. J Physiol Pharmacol 2009; 60 Suppl 7: 167-75.
29. Kadar K, Porcsalmy B, Kiraly M, et al. [Isolating, culturing and characterizing stem cells of human dental pulp origin]. Fogorv Sz 2009; 102: 175-81.
30. Kiraly M, Porcsalmy B, Pataki A, et al. Simultaneous PKC and cAMP activation induces differentiation of human dental pulp stem cells into functionally active neurons. Neurochemistry international 2009; 55: 323-32.
31. Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA 2003; 100: 5807-12.
32. Molnar B, Kadar K, Kiraly M, et al. [Isolation, cultivation and characterisation of stem cells in human periodontal ligament]. Fogorv Sz 2008; 101: 155-61.
33. Seo BM, Miura M, Gronthos S, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet 2004; 364: 149-55.
34. Clarke DL. Neural stem cells. Bone Marrow Transplant 2003; 32 Suppl 1: S13-7.
35. Grove JE, Bruscia E and Krause DS. Plasticity of bone marrowderived stem cells. Stem Cells 2004; 22: 487-500.
36. Bjornson CR, Rietze RL, Reynolds BA, Magli MC and Vescovi AL. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999; 283: 534-7.
37. Clarke DL, Johansson CB, Wilbertz J, et al. Generalized potential of adult neural stem cells. Science 2000; 288: 1660-3.
38. Galli R, Borello U, Gritti A, et al. Skeletal myogenic potential of human and mouse neural stem cells. Nat Neurosci 2000; 3: 986-91.
39. Scintu F, Reali C, Pillai R, et al. Differentiation of human bone marrow stem cells into cells with a neural phenotype: diverse effects of two specific treatments. BMC Neurosci 2006; 7: 14.
40. Yu J, He H, Tang C, et al. Differentiation potential of STRO-1+ dental pulp stem cells changes during cell passaging. BMC Cell Biol 2010; 11: 32.
41. Yang X, van der Kraan PM, van den Dolder J, et al. STRO-1 selected rat dental pulp stem cells transfected with adenoviralmediated human bone morphogenetic protein 2 gene show enhanced odontogenic differentiation. Tissue Eng 2007; 13: 2803-12.
42. Zhang W, Walboomers XF, Wolke JG, et al. Differentiation ability of rat postnatal dental pulp cells in vitro. Tissue Eng 2005; 11: 357-68.
43. Kemoun P, Laurencin-Dalicieux S, Rue J, et al. Human dental follicle cells acquire cementoblast features under stimulation by BMP-2/-7 and enamel matrix derivatives (EMD) in vitro. Cell Tissue Res 2007; 329: 283-94.
44. Thesleff I and Aberg T. Molecular regulation of tooth development. Bone 1999; 25: 123-5.
45. Tucker A and Sharpe P. The cutting-edge of mammalian development; how the embryo makes teeth. Nat Rev Genet 2004; 5: 499-508.
46. Kiraly M, Kadar K, Horvathy DB, et al. Integration of neuronally predifferentiated human dental pulp stem cells into rat brain in vivo. Neurochemistry international 2011; 59: 371-81.
47. Arthur A, Rychkov G, Shi S, Koblar SA and Gronthos S. Adult human dental pulp stem cells differentiate toward functionally active neurons under appropriate environmental cues. Stem Cells 2008; 26: 1787-95.
48. Ma J, Wang Y, Yang J, et al. Treatment of hypoxic-ischemic encephalopathy in mouse by transplantation of embryonic stem cellderived cells. Neurochemistry international 2007; 51: 57-65.
49. Baum BJ and O'Connell BC. In vivo gene transfer to salivary glands. Crit Rev Oral Biol Med 1999; 10: 276-83.
50. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-10.
51. Mulligan RC. The basic science of gene therapy. Science 1993; 260: 926-32.
52. Verma IM and Somia N. Gene therapy--promises, problems and prospects. Nature 1997; 389: 239-42.
53. Robbins PD and Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998; 80: 35-47.
54. Schaffer DV, Koerber JT and Lim KI. Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng 2008; 10: 169-94.
55. Barka T and Van der Noen HM. Retrovirus-mediated gene transfer into salivary glands in vivo. Hum Gene Ther 1996; 7: 613-8.
56. Barka T and van der Noen HM. Retrovirus-mediated gene transfer into rat salivary gland cells in vitro and in vivo. J Histochem Cytochem 1997; 45: 1533-45.
57. Shai E, Falk H, Honigman A, Panet A and Palmon A. Gene transfer mediated by different viral vectors following direct cannulation of mouse submandibular salivary glands. Eur J Oral Sci 2002; 110: 254-60.
58. Lewis P, Hensel M and Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992; 11: 3053-8.
59. Vetrini F and Ng P. Gene therapy with helper-dependent adenoviral vectors: current advances and future perspectives. Viruses 2010; 2: 1886-917.
60. Benihoud K, Yeh P and Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 440-7.
61. Amalfitano A, Hauser MA, Hu H, et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-33.
62. Goncalves MA. Adeno-associated virus: from defective virus to effective vector. Virol J 2005; 2: 43.
63. Daya S and Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-93.
64. Kok MR, Yamano S, Lodde BM, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum Gene Ther 2003; 14: 1605-18.
65. Voutetakis A, Bossis I, Kok MR, et al. Salivary glands as a potential gene transfer target for gene therapeutics of some monogenetic endocrine disorders. J Endocrinol 2005; 185: 363-72.
66. Yamano S, Huang LY, Ding C, et al. Recombinant adenoassociated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream. Hum Gene Ther 2002; 13: 287-98.
67. Fink DJ, DeLuca NA, Goins WF and Glorioso JC. Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci 1996; 19: 265-87.
68. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93: 11341-8.
69. Edelstein ML, Abedi MR and Wixon J. Gene therapy clinical trials worldwide to 2007--an update. J Gene Med 2007; 9: 833-42.
70. Mandel ID. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc 1989; 119: 298-304.
71. Pedersen AM, Bardow A, Jensen SB and Nauntofte B. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis 2002; 8: 117-29.
72. Catalan MA, Nakamoto T and Melvin JE. The salivary gland fluid secretion mechanism. J Med Invest 2009; 56 Suppl: 192-6.
73. Thaysen JH, Thorn NA and Schwartz IL. Excretion of sodium, potassium, chloride and carbon dioxide in human parotid saliva. Am J Physiol 1954; 178: 155-9.
74. Cassolato SF and Turnbull RS. Xerostomia: clinical aspects and treatment. Gerodontology 2003; 20: 64-77.
75. Ship JA, Pillemer SR and Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc 2002; 50: 535-43.
76. Delporte C, O'Connell BC, He X, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. Proc Natl Acad Sci USA 1997; 94: 3268-73.
77. Tran SD, Wang J, Bandyopadhyay BC, et al. Primary culture of polarized human salivary epithelial cells for use in developing an artificial salivary gland. Tissue Eng 2005; 11: 172-81.
78. Tran SD, Sugito T, Dipasquale G, et al. Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland. Tissue Eng 2006; 12: 2939-48.
79. Helmerhorst EJ and Oppenheim FG. Saliva: a dynamic proteome. J Dent Res 2007; 86: 680-93.
80. Isenman L, Liebow C and Rothman S. The endocrine secretion of mammalian digestive enzymes by exocrine glands. Am J Physiol 1999; 276: E223-32.
81. Leonora J, Tieche JM and Celestin J. Physiological factors affecting secretion of parotid hormone. Am J Physiol 1987; 252: E477-84.
82. Baum BJ, Berkman ME, Marmary Y, et al. Polarized secretion of transgene products from salivary glands in vivo. Hum Gene Ther 1999; 10: 2789-97.
83. Baum BJ, Voutetakis A and Wang J. Salivary glands: novel target sites for gene therapeutics. Trends Mol Med 2004; 10: 585-90.
84. O'Connell BC, Xu T, Walsh TJ, et al. Transfer of a gene encoding the anticandidal protein histatin 3 to salivary glands. Hum Gene Ther 1996; 7: 2255-61.
85. Adriaansen J, Perez P, Goldsmith CM, Zheng C and Baum BJ. Differential sorting of human parathyroid hormone after transduction of mouse and rat salivary glands. Hum Gene Ther 2008; 19: 1021-8.
86. Castle AM, Huang AY and Castle JD. Immunoglobulin-derived polypeptides enter the regulated secretory pathway in AtT-20 cells. FEBS Lett 1998; 439: 341-5.
87. Racz GZ, Perez-Riveros P, Adriaansen J, Zheng C and Baum BJ. In vivo secretion of the mouse immunoglobulin G Fc fragment from rat submandibular glands. J Gene Med 2009; 11: 580-7.
88. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
89. Jin Q, Cirelli JA, Park CH, et al. RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis. J Periodontol 2007; 78: 1300-8.
90. Davis AE, 3rd. The pathogenesis of hereditary angioedema. Transfus Apher Sci 2003; 29: 195-203.
91. Davis AE, 3rd. Biological effects of C1 inhibitor. Drug News Perspect 2004; 17: 439-46.
92. Voutetakis A, Kok MR, Zheng C, et al. Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. Proc Natl Acad Sci USA 2004; 101: 3053-8.
93. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-72.
94. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-50.
95. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
96. Yi Y, Hahm SH and Lee KH. Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther 2005; 5: 25-35.
97. Kimelman N, Pelled G, Helm GA, et al. Review: gene-and stem cell-based therapeutics for bone regeneration and repair. Tissue Eng 2007; 13: 1135-50.
98. Yang M, Ma QJ, Dang GT, et al. In vitro and in vivo induction of bone formation based on ex vivo gene therapy using rat adiposederived adult stem cells expressing BMP-7. Cytotherapy 2005; 7: 273-81.
99. Yang X, van der Kraan PM, Bian Z, et al. Mineralized tissue formation by BMP2-transfected pulp stem cells. J Dent Res 2009; 88: 1020-5.
100. Lin H, Shabbir A, Molnar M, et al. Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells. J Cell Physiol 2008; 216: 458-68.
101. Shum KT, Chan C, Leung CM and Tanner JA. Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling. Biochem J 2011; 434: 493-501.
102. Negroni E, Vallese D, Vilquin JT, et al. Current advances in cell therapy strategies for muscular dystrophies. Expert Opin Biol Ther 2011; 11: 157-76.
103. Giordano A, Galderisi U and Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35.
104. Westphal M and Lamszus K. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 2011; 12: 495-508.
105. Tabatabai G, Wick W and Weller M. Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? Discov Med 2011; 11: 529-36.
106. Kaji K, Norrby K, Paca A, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458: 771-5.
107. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458: 766-70.
108. Markoulaki S, Hanna J, Beard C, et al. Transgenic mice with defined combinations of drug-inducible reprogramming factors. Nat Biotechnol 2009; 27: 169-71.
109. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136: 964-77.
110. Sommer CA, Sommer AG, Longmire TA, et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010; 28: 64-74.
111. Ivics Z, Li MA, Mates L, et al. Transposon-mediated genome manipulation in vertebrates. Nat Methods 2009; 6: 415-22.
112. Zhou Q, Brown J, Kanarek A, Rajagopal J and Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455: 627-32.
113. Heinrich C, Blum R, Gascon S, et al. Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biol 2010; 8: e1000373.
114. Ieda M, Fu JD, Delgado-Olguin P, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142: 375-86.
115. Efe JA, Hilcove S, Kim J, et al. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 2011; 13: 215-22.